Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
|Articles|September 18, 2021
- Ophthalmology Times: September 15, 2021
- Volume 46
- Issue 15
Phone a friend
Author(s)Jon Carter
See the latest cartoon!
Advertisement
Articles in this issue
almost 5 years ago
Study targets use of swept-source OCT to measure macular hole volumealmost 5 years ago
POAAGG study targets gene therapy options for glaucomaabout 5 years ago
COVID-19: The Chinese experience early in the pandemicabout 5 years ago
Study targets dry eye disease in postmenopausal womenabout 5 years ago
Corneal mechanical sensitivity in individuals with chronic painabout 5 years ago
Cataract surgery pearls for cases with poor mydriasis, zonulesabout 5 years ago
Virtual reality simulator will boost vitreoretinal surgery trainingAdvertisement
Related to this article
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Two investigational pipeline therapies take aim at the root causes of dry eye disease
Dry eye care pivots to root-cause diagnosis and personalized biologics/devices,
Cataract surgery becomes refractive: learn how IOL choices and preop counseling across distance, intermediate and near turn 20/20 into 20/happy.
Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.
June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Brepocitinib meets all Phase 3 end points in noninfectious uveitis
2
Demodex blepharitis: Diagnosis, treatment response, and recurrence
3
Myopia control using spectacle lenses with highly aspherical lenslets
4
CHMP recommends ranibizumab biosimilar Fovlussea for retinal disease
5